ReviewBiomaterials science2025
Fucoidan based hydrogel biomaterials for tissue engineering.
Review in Biomaterials science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Gummies: From Confectionery to Functional Hydrogel-Based Bioactive Delivery Systems.Gels (Basel, Switzerland) · 2026Review
- Engineering a Compartmentalized Multi-Cell Co-Culture Hydrogel System Using Beeswax/Fucoidan/Alginate for Cultured Meat Modeling.Foods (Basel, Switzerland) · 2026Article
- Fucoidan and alginate from brown seaweeds: extraction, structural diversity, biocompatibility, biodegradability, and biomedical applications.Frontiers in plant science · 2026Review
- Research Progress of Natural Polysaccharide-Based Hydrogels in Skin Tissue Regeneration.Gels (Basel, Switzerland) · 2025Review
- Multifunctional Carboxymethyl Chitosan/Sodium Alginate/Fucoidan Hydrogel as a Dressing for Hemostasis and Skin Wound Healing.Gels (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Biopolymer-based biomaterials have gained significant attention in tissue engineering for their ability to support cell adhesion, proliferation, and tissue regeneration. Among these, biomaterials that naturally reduce inflammation, modulate immune responses, and restore redox balance offer substantial benefits when used in combination with cells or growth factor-based therapies. Fucoidan is an FDA-approved sulfated polysaccharide, which exhibits excellent biocompatibility and has been widely studied for applications in immunomodulation, wound healing, drug delivery, and regenerative medicine. Despite its broad potential, comprehensive review articles that summarize recent advances, critically evaluate existing literature, and identify future research opportunities remain limited. In this review, we provide an overview of the structure of fucoidan and discuss mechanisms of its bioactivity. We highlight recent advances in the design of fucoidan-containing hydrogels, focusing on their applications in tissue regeneration. Through case studies in wound healing and neural tissue repair, we illustrate how fucoidan contributes to key regenerative processes, including immune modulation, oxidative stress reduction, and enhanced therapeutic drug delivery. Additionally, we examine the major challenges that hinder the progress and clinical translation of fucoidan-based hydrogels such as variability in chemical composition, the influence of molecular weight and sulfation level on bioactivity, and limitations in crosslinking to form fucoidan hydrogels. Overall, this review aims to highlight the underappreciated potential of fucoidan as a versatile immunomodulatory biomaterial for hydrogel development in tissue engineering and regenerative medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.